FRANKLIN, Tenn.--(BUSINESS WIRE)--Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that the Company will present at the 42nd Annual J.P. Morgan Healthcare Conference, January 8-11, 2024, at The Westin St. Francis, San Francisco, California. In connection with the conference, there will be a webcast of the Company’s presentation available on the Company’s website starting at 2:15 p.m. Pacific Time/4:15 p.m. Central Time on Tuesday, January 9, 2024. The live webcast of the presentation will be ...

Financial Data and Key Metrics Changes - Acadia reported a year-over-year revenue growth of 12.5%, reaching $750.3 million for Q3 2023 [22] - Adjusted EBITDA increased by 13.4% to $175.9 million compared to $155.1 million in Q3 2022 [23] - Adjusted EPS grew by 13.8% to $0.91 per diluted share, up from $0.80 in the same quarter last year [23] - Same facility revenue increased by 13% year-over-year, driven by both volume and rate improvements [8] Business Line Data and Key Metrics Changes - All service lines, including acute, specialty, and CTC, experienced strong performance, with acute and specialty seeing the most significant volume growth [32] - The CTC service line expanded to 155 locations across 32 states, with plans to open six new CTCs in 2023 [11] - The company added 204 beds to existing facilities in the first nine months of 2023, on track to meet the goal of approximately 300 bed additions by year-end [10] Market Data and Key Metrics Changes - The company noted a decrease in wage inflation from 7.5% in Q1 to 5.7% in Q3 2023, indicating improved labor trends [9] - The impact of Medicaid redetermination has been manageable, with approximately 40% of patients having completed the process [34] Company Strategy and Development Direction - Acadia's growth strategy includes five defined pathways: facility expansions, de novo facilities, joint ventures, acquisitions, and extending the continuum of care [17] - The company is focused on developing wholly owned de novo facilities in underserved markets, with two new hospitals expected to open by year-end [10] - Joint ventures are a significant growth pathway, with 20 partnerships representing 21 hospitals, and a robust pipeline for future collaborations [14] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism regarding the ongoing demand for behavioral health services and the company's ability to meet this demand through strategic execution [7] - The company anticipates continued growth in 2024, with significant opportunities through defined pathways and joint ventures [18] Other Important Information - Acadia has maintained a strong financial position with $99.6 million in cash and $520 million available under its revolving credit facility [25] - The company announced a definitive agreement to acquire Turning Point Centers, which will add 76 beds and potentially 48 more over time [15] Q&A Session Summary Question: Inquiry about professional liability reserves - Management confirmed that the increase in reserves was part of the regular review process and not due to changes in claims volume [30] Question: Update on service line performance and Medicaid redetermination - Management indicated strong performance across all service lines, with no significant impact from Medicaid redetermination on patient volume [32] Question: Thoughts on payment rates and payer classes - Management expressed satisfaction with rate negotiations, expecting continued strong rates into Q4 and 2024 [37] Question: Discussion on joint ventures and partnerships - Management noted ongoing interest from health systems in partnerships to address behavioral health needs, indicating a strong pipeline for future joint ventures [41] Question: Impact of construction costs on future growth - Management acknowledged previous spikes in construction costs but indicated improved management strategies moving forward [59] Question: Corporate overhead expectations for next year - Management expects corporate costs to level off and continue to build leverage as a percentage of revenue [65]

PART I [PART I – FINANCIAL INFORMATION](index=3&type=section&id=PART%20I%20%E2%80%93%20FINANCIAL%20INFORMATION) This section presents the company's financial statements and related disclosures for the period ended September 30, 2023 [Financial Statements](index=3&type=section&id=Item%201.%20Financial%20Statements) The company's Q3 2023 financial statements reflect revenue growth, a significant net loss due to a $394.2 million legal settlement, and increased assets and liabilities [Condensed Consolidated Balance Sheets](index=3&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) As of September 30, 2023, total assets increased to **$5.35 billion** and total liabilities rose to **$2.54 billion**, primarily due to a significant increase in accrued legal settlement liabilities Condensed Consolidated Balance Sheet Highlights (in thousands) | Account | Sep 30, 2023 | Dec 31, 2022 | | :--- | :--- | :--- | | **Total current assets** | $703,475 | $506,125 | | **Total assets** | **$5,346,218** | **$4,987,901** | | **Total current liabilities** | $864,890 | $388,326 | | Other accrued liabilities | $539,947 | $110,592 | | **Total liabilities** | **$2,536,074** | **$2,086,917** | | **Total equity** | $2,712,562 | $2,812,727 | [Condensed Consolidated Statements of Operations](index=4&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) Q3 2023 revenue grew to **$750.3 million**, but a **$394.2 million** legal settlement resulted in a net loss of **$217.7 million**, contrasting with prior year's net income Q3 2023 vs Q3 2022 Statement of Operations (in thousands, except per share data) | Metric | Q3 2023 | Q3 2022 | | :--- | :--- | :--- | | Revenue | $750,334 | $666,732 | | Legal settlements expense | $394,181 | $0 | | (Loss) income before income taxes | $(287,398) | $97,102 | | Net (loss) income attributable to Acadia | $(217,710) | $71,099 | | Diluted (Loss) earnings per share | $(2.39) | $0.78 | Nine Months 2023 vs 2022 Statement of Operations (in thousands, except per share data) | Metric | Nine Months 2023 | Nine Months 2022 | | :--- | :--- | :--- | | Revenue | $2,185,938 | $1,935,104 | | Legal settlements expense | $394,181 | $0 | | (Loss) income before income taxes | $(105,325) | $286,071 | | Net (loss) income attributable to Acadia | $(79,396) | $212,015 | | Diluted (Loss) earnings per share | $(0.87) | $2.31 | [Condensed Consolidated Statements of Cash Flows](index=6&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Net cash from operations increased to **$346.0 million** for the nine months ended September 30, 2023, driven by non-cash charges, despite higher cash used in investing activities Cash Flow Summary for Nine Months Ended Sep 30 (in thousands) | Cash Flow Activity | 2023 | 2022 | | :--- | :--- | :--- | | Net cash provided by operating activities | $346,036 | $267,025 | | Net cash used in investing activities | $(287,051) | $(213,810) | | Net cash used in financing activities | $(57,043) | $(93,609) | | **Net increase (decrease) in cash** | **$1,942** | **$(40,394)** | [Notes to Condensed Consolidated Financial Statements](index=7&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) Notes detail company operations, revenue sources, and debt, highlighting the **$394.2 million** legal settlement liability for the Desert Hills Litigation - As of September 30, 2023, the Company operated **253 behavioral healthcare facilities** with approximately **11,100 beds** in 39 states and Puerto Rico[16](index=16&type=chunk) Revenue by Service Type (in thousands) | Service Type | Q3 2023 | Q3 2022 | | :--- | :--- | :--- | | Acute inpatient psychiatric facilities | $382,406 | $340,929 | | Specialty treatment facilities | $158,705 | $145,799 | | Comprehensive treatment centers | $129,645 | $106,679 | | Residential treatment centers | $79,578 | $73,325 | Revenue by Payor Type (Q3 2023 vs Q3 2022) | Payor | Q3 2023 % | Q3 2022 % | | :--- | :--- | :--- | | Medicaid | 53.4% | 51.5% | | Commercial | 28.3% | 29.0% | | Medicare | 15.6% | 15.2% | | Self-Pay | 2.1% | 3.0% | - On October 30, 2023, the company entered into settlement agreements for the Desert Hills Litigation for an aggregate amount of **$400.0 million**, with a legal settlements liability of **$394.2 million** recorded at September 30, 2023[49](index=49&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=22&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses strong revenue growth driven by increased patient volumes, acknowledging the **$394.2 million** legal settlement's impact on net income, while affirming sufficient liquidity for the payment - For the year ending December 31, 2023, the company expects to add approximately **300 beds** to existing facilities and open two wholly-owned facilities, two joint venture facilities, and six Comprehensive Treatment Centers (CTCs)[78](index=78&type=chunk) Same Facility Operating Data Growth (Q3 2023 vs Q3 2022) | Metric | % Change | | :--- | :--- | | Revenue growth | 13.0% | | Patient days growth | 6.0% | | Admissions growth | 5.1% | | Revenue per patient day growth | 6.6% | - The company intends to pay the **$400.0 million** Desert Hills settlement from a combination of insurance, cash on hand, and existing credit lines, and believes existing liquidity will be sufficient[121](index=121&type=chunk) - As of September 30, 2023, the company had **$516.5 million** of availability under its Revolving Facility[123](index=123&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=35&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company's primary market risk is interest rate fluctuations on its **$434.5 million** variable-rate debt, with a 1% rate increase impacting pretax income by **$4.3 million** - The company's interest expense is sensitive to market interest rates, with **$434.5 million** of variable-rate debt outstanding at September 30, 2023[135](index=135&type=chunk) - A hypothetical **1% increase** in interest rates would decrease the company's pretax income by approximately **$4.3 million** on an annual basis[135](index=135&type=chunk) [Controls and Procedures](index=35&type=section&id=Item%204.%20Controls%20and%20Procedures) Disclosure controls and procedures were deemed effective as of September 30, 2023, with no material changes to internal control over financial reporting during the quarter - Management concluded that the company's disclosure controls and procedures were effective as of the end of the period covered by the report[136](index=136&type=chunk) - No changes in internal control over financial reporting occurred during the third quarter of 2023 that have materially affected, or are reasonably likely to materially affect, internal controls[137](index=137&type=chunk) PART II [PART II – OTHER INFORMATION](index=36&type=section&id=PART%20II%20%E2%80%93%20OTHER%20INFORMATION) This section provides additional information beyond the financial statements, including legal proceedings, risk factors, equity transactions, and exhibits [Legal Proceedings](index=36&type=section&id=Item%201.%20Legal%20Proceedings) This section refers to Note 12 for details on legal matters, particularly the Desert Hills Litigation, which led to a **$394.2 million** charge and a **$400 million** settlement - Information regarding legal proceedings is detailed in Note 12 of the financial statements, which covers the significant Desert Hills Litigation[139](index=139&type=chunk)[49](index=49&type=chunk) [Risk Factors](index=36&type=section&id=Item%201A.%20Risk%20Factors) No material changes to previously disclosed risk factors were reported in the current period - There have been no material changes to the risk factors disclosed in the company's prior periodic reports[140](index=140&type=chunk) [Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Repurchases of Equity Securities](index=36&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%2C%20Use%20of%20Proceeds%20and%20Issuer%20Repurchases%20of%20Equity%20Securities) During Q3 2023, the company withheld **14,390** common shares for employee tax obligations related to restricted stock vesting, not part of a repurchase plan Shares Withheld for Tax Obligations (Q3 2023) | Period | Total Number of Shares Purchased | | :--- | :--- | | July 2023 | 6,082 | | August 2023 | 3,542 | | September 2023 | 4,766 | | **Total** | **14,390** | [Other Information](index=36&type=section&id=Item%205.%20Other%20Information) No directors or officers adopted or terminated Rule 10b5-1 or non-Rule 10b5-1 trading arrangements during Q3 2023 - During the three months ended September 30, 2023, none of the Company's directors or officers adopted or terminated any Rule 10b5-1 trading arrangement[143](index=143&type=chunk) [Exhibits](index=37&type=section&id=Item%206.%20Exhibits) This section lists all exhibits filed with the Form 10-Q, including corporate governance documents, employment agreements, and required certifications - The report includes several exhibits, such as executive employment agreements, separation agreements, and certifications required by the Sarbanes-Oxley Act[145](index=145&type=chunk)

Acadia Healthcare Company, Inc. (NASDAQ:ACHC) Q2 2023 Earnings Conference Call July 28, 2023 9:30 AM ET Company Participants Gretchen Hommrich – Vice President-Investor Relations Chris Hunter – Chief Executive Officer Heather Dixon – Chief Financial Officer Conference Call Participants Andrew Mok – UBS Whit Mayo – Leerink Partners A.J. Rice – Credit Suisse John Ransom – Raymond James Gary Taylor – Cowen Pito Chickering – Deutsche Bank John Ransom – Raymond James Brian Tanquilut – Jefferies Operator Good day ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission File Number: 001-35331 Acadia Healthcare Company, Inc. (Exact name of registrant as specified in its charter) Delaware ...

Financial Data and Key Metrics - Revenue for Q1 2023 increased by 14.2% YoY to $704.3 million, driven by robust demand for behavioral health services [12] - Adjusted EBITDA grew by 11.6% YoY to $151.3 million, and adjusted EPS increased by 11.9% YoY to $0.75 [12] - Same-facility revenue grew by 13.3% YoY, with patient day growth of 6.5% and revenue per day growth of 6.4% [6] - Labor costs were in line with expectations, with base wage inflation at 7.5% and premium pay showing sequential improvement [7] Business Line Data and Key Metrics - The company added 106 beds to existing facilities in Q1, with a target of adding approximately 300 beds in 2023 [7] - Two new de novo facilities are planned for 2023, including a 101-bed adult hospital in Chicago and an 80-bed facility in Indio, California [8] - The company aims to add at least six Comprehensive Treatment Centers (CTCs) in 2023, expanding its network of 151 CTCs across 32 states [8] - Strategic partnerships with health systems are progressing, with 19 joint venture facilities in various stages of development [8] Market Data and Key Metrics - The company operates 250 facilities with 23,000 employees, serving diverse markets across the U.S. [6] - Record patient volumes were achieved in Q1, with strong demand across service lines, markets, and payers [6] - The labor market remains tight, but the company has seen improvements in recruiting and retention, particularly for RNs and BHAs [16][17] Company Strategy and Industry Competition - The company’s growth strategy focuses on five pathways: facility expansions, de novo facilities, strategic partnerships, selective acquisitions, and extending the continuum of care [7][8][9] - Acadia is investing in technology and differentiated services to improve care delivery and clinical outcomes [11] - The company published its inaugural sustainability report, highlighting its commitment to environmental, social, and governance (ESG) initiatives [11] Management Commentary on Operating Environment and Future Outlook - Management highlighted the urgent need for behavioral health services in the U.S., with suicide being the second leading cause of death among Americans aged 15-24 [5] - The company expects continued strong demand for its services and is focused on expanding access to care in underserved markets [10] - Labor market conditions are improving, with wage inflation expected to moderate further in 2023 [7][16] Other Important Information - The company has $63.8 million in cash and cash equivalents and $485 million available under its revolving credit facility, with a net leverage ratio of approximately 2.2 [12] - Guidance for 2023 includes revenue of $2.82 billion to $2.88 billion, adjusted EBITDA of $635 million to $675 million, and adjusted EPS of $3.10 to $3.40 [12] Q&A Session Summary Labor Trends and Wage Inflation - Base wage inflation improved from 8% in Q4 2022 to 7.5% in Q1 2023, with total wage inflation at 7.1% [16] - The company has implemented strategies to improve recruiting and retention, including partnerships with nursing schools and tuition reimbursement programs [17] Medicaid Redeterminations - Medicaid redetermination is in early stages, with 15 million individuals expected to lose coverage, but 75% of those may transition to commercial insurance [20] - The company has implemented patient education and support programs to mitigate the impact of redetermination [22] CTC Business and Opioid Settlement Funds - The company plans to open six CTCs in 2023 and accelerate to 14 in 2024, with potential benefits from opioid settlement funds [36] - The CTC business has strong margins, with many locations exceeding the company average of 28% [38] Labor Cost and Corporate Overhead - Wage inflation is expected to moderate to 3%-5% by the end of 2023, with improvements in labor cost management [42] - Corporate overhead increased due to investments in IT, HR, and marketing, but these are expected to drive long-term efficiencies [45] IT Initiatives and EHR Rollout - The company is piloting an EHR system, with early benefits seen in employee engagement and compliance [48] - IT investments are expected to improve patient experience, data analytics, and operational efficiency [50] Cash Flow and Working Capital - Q1 operating cash flow was $44 million, in line with expectations, with seasonal impacts from working capital and payroll timing [59]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission File Number: 001-35331 Acadia Healthcare Company, Inc. (Exact name of registrant as specified in its charter) Delaware ...

Raymond James Institutional Investors Conference Orlando, FL | March 7, 2023 Safe Harbor  Some of the statements made in this presentation constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include any statements that address future results or occurrences. In some cases, you can identify forward-looking statements by terminology such as “may,” “might”, “will”, “should,” “could” or the negative thereof. Generally, the ...

Acadia Healthcare Company, Inc. (NASDAQ:ACHC) Q4 2022 Earnings Conference Call February 28, 2023 8:00 AM ET Company Participants Gretchen Hommrich - Vice President, Investor Relations Chris Hunter - Chief Executive Officer David Duckworth - Chief Financial Officer Conference Call Participants A.J. Rice - Credit Suisse Whit Mayo - SVB Securities Kevin Fischbeck - Bank of America Andrew Mok - UBS Gary Taylor - Cowen Kieran Ryan - Deutsche Bank John Ransom - Raymond James Operator Good morning and welcome to A ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35331 ACADIA HEALTHCARE COMPANY, INC. (Exact name of registrant as specified in its charter) Delaware 45-2492228 ( ...